The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype

被引：0
|
作者：
Kenjiro Aogi
Masayuki Yoshida
Yoshiaki Sagara
Shunji Kamigaki
Minoru Okazaki
Jumpei Funai
Toshio Fujimoto
Masakazu Toi
Toshiaki Saeki
Shigemitsu Takashima
机构：
[1] Shikoku Cancer Center,Department of Breast Oncology
[2] Seirei Hamamatsu General Hospital,Department of Breast Surgery
[3] Sagara Hospital,Division of Breast Surgery
[4] Sakai Municipal Hospital,Department of Surgery
[5] Sapporo Breast Surgical Clinic,Science Communications
[6] Eli Lilly Japan K.K.,Medical Science
[7] Eli Lilly Japan K.K.,Department of Surgery
[8] Kyoto University Graduate School of Medicine,Department of Breast Oncology
[9] Saitama Medical University International Medical Center,undefined
[10] Shikoku Cancer Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Anthracycline-pretreated metastatic breast cancer; Triple negative; Gemcitabine; Paclitaxel; Phase I/II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1007 / 1015
页数：8
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2022, 25 (12) : S184 - S184
  • [42] Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
    Lu, Fei
    Hou, Yu
    Chen, Zhengting
    Jiang, Jie
    He, Xi
    Xia, Yaoxiong
    Cao, Ke
    Chang, Li
    Li, Wenhui
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [43] Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer
    Sánchez-Rovira, P
    Jaén, A
    González, E
    Porras, I
    Dueñas, R
    Medina, B
    Mohedano, N
    Fernández, M
    Martos, M
    Lozano, A
    Carrasco, E
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 44 - 47
  • [44] Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer
    Mayer, E. L.
    Miller, K.
    O'Shaughnessy, J.
    Dickler, M.
    Vogel, C.
    Leyland-Jones, B.
    Steelman, L.
    Robinson, M.
    Kuriyama, N.
    Agarwal, S.
    CANCER RESEARCH, 2012, 72
  • [45] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    F Cappuzzo
    F Mazzoni
    A Gennari
    S Donati
    B Salvadori
    C Orlandini
    G L Cetto
    A Molino
    E Galligioni
    M Mansutti
    S Tumolo
    A Lucentini
    F Valduga
    S Bartolini
    L Crinò
    P F Conte
    British Journal of Cancer, 2004, 90 : 31 - 35
  • [46] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
    Cappuzzo, F
    Mazzoni, F
    Gennari, A
    Donati, S
    Salvadori, B
    Orlandini, C
    Cetto, GL
    Molino, A
    Galligioni, E
    Mansutti, M
    Tumolo, S
    Lucentini, A
    Valduga, F
    Bartolini, S
    Crinò, L
    Conte, PF
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
  • [47] Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer
    Baltali, E
    Altundag, MK
    Güler, N
    Özisik, Y
    Firat, D
    Baran, I
    Tekuzman, G
    TUMORI, 2002, 88 (03) : 200 - 203
  • [48] Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
    Tredan, Olivier
    Campone, Mario
    Jassem, Jacek
    Vyzula, Rostislav
    Coudert, Bruno
    Pacilio, Carmen
    Prausova, Jana
    Hardy-Bessard, Anne-Claire
    Arance, Ana
    Mukhopadhyay, Pralay
    Aloe, Alessandra
    Roche, Henri
    CLINICAL BREAST CANCER, 2015, 15 (01) : 8 - 15
  • [49] Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Park, Yeon Hee
    Im, Seock-Ah
    Kim, Sung-Bae
    Sohn, Joo Hyuk
    Lee, Keun Seok
    Chae, Yee Soo
    Lee, Ki Hyeong
    Kim, Jee Hyun
    Im, Young-Hyuck
    Kim, Ji-Yeon
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Ahn, Jin-Hee
    Kim, Gun Min
    Park, In Hae
    Lee, Soo Jung
    Han, Hye Sook
    Kim, Se Hyun
    Jung, Kyung Hae
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 385 - 393
  • [50] Safety and efficacy of first-line docetaxel (DXL) - gemcitabine (GMZ) in metastatic breast cancer (MBC)
    Bensalem, A.
    Bouzid, K.
    EJC SUPPLEMENTS, 2005, 3 (02): : 131 - 131
12345